Boryung KRX:003850KOSPI

보령 · Korean news coverage and regulatory filings, organized.

Articles, 24h1
Articles, 7 days27
DART filings, 7 days2
Articles tracked267since Sep 11

In Q2 2026, Boryung reported revenue of ₩280bn, up 11.2% year on year, and operating profit of ₩23.8bn. Boryung (보령) appeared in 27 Korean news articles and 2 DART filings over the past seven days. Coverage peaked on Oct 28 with 23 articles. The most common catalyst was clinical & approvals (8).

Filing signals M&A / stake deal Treasury share sale Screener

Boryung quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩280bn+11.2%₩23.8bn
margin 8.5%
₩24.1bn
Q1 2026₩255bn+6.2%₩20.2bn
margin 7.9%
₩41.4bn
Q4 2025 derived₩245bn-4.5%−₩649m
margin −0.3%
₩21.1bn
Q3 2025₩280bn+3.3%₩29.4bn
margin 10.5%
₩34.0bn
Q2 2025₩252bn-1.6%₩25.4bn
margin 10.1%
₩8.9bn
Q1 2025₩241bn+3.0%₩10.9bn
margin 4.5%
₩349m
Q4 2024 derived₩257bn+11.1%₩14.5bn
margin 5.7%
₩13.2bn
Q3 2024₩271bn+30.1%₩19.5bn
margin 7.2%
₩9.4bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Boryung top stories 2 weeks, by number of outlets

  1. 1
    보령, 3Q 누적 영업익 694억…지난해 연간 실적 넘어
    14 outlets · 14 articlesFirst report Oct 22 12:41 메디파나뉴스
  2. 2
    보령, 임시주총서 영업부문 자회사 분할 승인…내년 1월 출범
    11 outlets · 11 articlesFirst report Oct 28 11:47 MTN
  3. 3
    보령, 항암신약 '보스몰리십' 임상 2상 환자 모집 완료
    7 outlets · 7 articlesFirst report Oct 19 09:13 FETVClinical trial
  4. 4
    보령, 임시주총서 ETC 영업부문 물적분할 승인
    4 outlets · 4 articlesFirst report Oct 28 12:10 메디포뉴스
  5. 5
    보령, 3분기 누적 영업이익 694억 원...전년 연간 실적 돌파
    3 outlets · 3 articlesFirst report Oct 22 13:37 메드월드뉴스
  6. 6
    [바이오스냅] 보령, 주총서 물적분할 승인…내년 1월 자회사 신설
    3 outlets · 3 articlesFirst report Oct 28 15:32 연합뉴스경제

Latest Boryung news Korean headlines